aim 3  (Garmin Ltd)

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor taniborbactam against metallo-β-lactamases

doi: 10.1128/aac.00991-23

Figure Lengend Snippet: Susceptibility testing of β-lactams for metallo-β-lactamase-producing E. coli TOP10 recombinant strains a

Article Snippet: TABLE 1 Strain (β-lactamase produced) Ambler class b Minimal inhibitory concentrations (μg/mL) Ceftazidime Ceftazidime-TAN Cefepime Cefepime-TAN E. coli TOP10 – ≤0.06 ≤0.03 ≤0.06 ≤0.03 E. coli ATCC 25922 – ≤0.06 ≤0.03 ≤0.06 ≤0.03 E. coli NCTC 13353 A >64 1 >64 1 E. coli NDM-1 B1 >256 256 16 0.5 E. coli NDM-2 B1 >256 256 8 0.25 E. coli NDM-4 B1 >256 256 16 0.5 E. coli NDM-5 B1 >256 256 16 0.5 E. coli NDM-7 B1 >256 128 8 0.25 E. coli NDM-9 B1 >256 >256 16 16 E. coli NDM-14 B1 >256 256 32 0.5 E. coli NDM-19 B1 >256 128 4 ≤0.03 E. coli NDM-30 B1 >256 >256 2 2 E. coli NDM-35 B1 >256 64 8 0.5 E. coli NDM-47 B1 >256 128 8 0.5 E. coli VIM-1 B1 64 2 16 1 E. coli VIM-1-Ala148Val B1 256 2 8 0.5 E. coli VIM-2 B1 32 0.06 0.25 ≤0.03 E. coli VIM-2-Val148Ala B1 32 0.5 0.25 0.06 E. coli VIM-2-Glu149Lys B1 128 128 4 4 E. coli VIM-4 B1 128 0.25 0.5 ≤0.03 E. coli VIM-5 B1 64 0.125 ≤0.06 ≤0.03 E. coli VIM-6 B1 16 1 0.25 ≤0.03 E. coli VIM-19 B1 64 0.25 1 ≤0.03 E. coli VIM-53 B1 16 0.06 0.125 ≤0.03 E. coli VIM-83 B1 256 256 64 64 E. coli IMP-1 B1 >256 >256 16 16 E. coli IMP-2 B1 >256 >256 16 16 E. coli IMP-4 B1 >256 >256 16 16 E. coli IMP-13 B1 64 64 2 2 E. coli SIM-1 B1 2 2 ≤0.06 ≤0.03 E. coli DIM-1 B1 2 0.125 ≤0.06 ≤0.03 E. coli GIM-1 B1 8 0.25 ≤0.06 ≤0.03 E. coli SPM-1 B1 128 4 4 ≤0.03 E. coli PFM-1 B2 ≤0.06 ≤0.03 ≤0.06 ≤0.03 E. coli AIM-1 B3 4 4 ≤0.06 ≤0.03 Imipenem Imipenem-TAN E. coli ATCC 25922 – 0.25 0.25 E. coli PFM-1 B2 2 2 Open in a separate window a Data of minimal inhibitory concentrations by microdilution; TAN, taniborbactam at 4 μg/mL. b (-) Not applicable.

Techniques: Recombinant, Produced

Journal: BMJ Mental Health

Article Title: Prevalence of spontaneous movement disorders (dyskinesia, parkinsonism, akathisia and dystonia) in never-treated patients with chronic and first-episode psychosis: a systematic review and meta-analysis

doi: 10.1136/bmjment-2024-301184

Figure Lengend Snippet: Studies reporting on spontaneous movement disorders

Article Snippet: McCreadie et al , – , AIMS (S&K) SAS ≥3 , 35 , 15 , – , – , High.

Techniques: